|
Patent landscape, scope, and claims: |
Analysis of US Patent RE47691: Scope, Claims, and Patent Landscape
What does Patent RE47691 cover?
Patent RE47691 is a reissue patent filed by Eli Lilly and Company that primarily focuses on compounds and methods related to a specific class of kinase inhibitors. This patent is a reissue of U.S. Patent 8,650,148, covering novel chemical entities and their use in treating diseases, including cancer.
Key features:
- Chemical scope: The patent claims cover substituted pyrimidine derivatives, a class of kinase inhibitors targeted at specific enzymes involved in cell proliferation.
- Therapeutic applications: The compounds are claimed for use in the treatment of diseases, including various cancers, inflammatory diseases, and metabolic disorders.
- Methods of synthesis: The patent includes claims on the synthetic routes for preparing the compounds.
- Pharmacological data: In vitro and in vivo data demonstrate the inhibitory activity against specific kinases, notably Janus kinase (JAK) family members.
What are the primary claims?
Core claims:
- Compound claims: The patent claims a set of substituted pyrimidines with specific structural features, including particular substituents at defined positions. For example, claim 1 covers a compound with a pyrimidine core substituted with specific groups at positions 2, 4, and 6.
- Use claims: Claims define the use of the compounds in methods of treating diseases, including administering a therapeutically effective amount to a subject suffering from a disease mediated by kinase activity.
- Process claims: Methods of synthesizing the compounds are included, such as steps involving particular reagents and reaction conditions.
- Formulation claims: Claims may extend to pharmaceutical compositions comprising the compounds, along with excipients.
Claim limitations:
- The scope includes specific structural variants, with chemical moieties defined broadly to encompass many derivatives.
- Claims also specify the preferred substituents and chemical properties to optimize kinase inhibition activity.
Important claim considerations:
- The claims are relatively broad in defining the substituted pyrimidine derivatives, but they limit scope through specific structural features.
- Use claims are tied to therapeutic indications, specifically kinase-mediated conditions.
Patent landscape analysis
Competitive patents:
- Multiple patents and applications cover kinase inhibitors, especially JAK inhibitors, which are a focus of RE47691.
- Similar patents include Bristol-Myers Squibb’s multiple JAK inhibitor patents, and patents assigned to Pfizer, such as US Patent 9,580,097, covering kinase inhibitors with similar structural motifs.
- The landscape shows intense activity in this area, with key players filing broad compositions and use claims for kinase inhibitors targeting diseases like autoimmune and oncologic conditions.
Patent families:
- RE47691 is part of a patent family that includes counterparts and continuations claiming various derivatives, formulations, and specific uses.
- The original patent's priority date is 2010, with the reissue filed in 2015 to correct or broaden claims.
Litigation and validity:
- The patent faces potential challenges from third parties due to broad claims overlapping with other kinase inhibitor patents.
- No significant litigation noted for RE47691 to date, but its enforceability depends on the novelty and non-obviousness of the claims, given the crowded patent landscape.
Filing and expiry:
- Filed in 2010, granted in 2014, and reissued in 2015.
- Expected expiration around 2030-2035, assuming patent term extensions are granted under US law.
Broader patent landscape implications
- The kinase inhibitor space remains highly competitive.
- Key patents focusing on JAK, TEC, and TYK kinase classes form a dense patent thicket.
- Innovators often rely on narrow claims or specific compound claims to avoid infringement.
- Patent expiration timelines are critical for market entry and generic competition planning.
Key Takeaways
- RE47691 claims a class of substituted pyrimidine compounds for kinase inhibition, primarily targeting JAK kinases.
- The claims are broad but structured around specific chemical substitutions, with therapeutic methods included.
- The patent landscape is densely populated with kinase inhibitor patents, requiring careful patent clearance strategies.
- Filing dates place expiration around 2030-2035, with ongoing patent filings possibly extending the family.
- Enforcement will depend on claim validity, prior art, and the specificity of the compounds.
FAQs
1. How does RE47691 compare to other kinase inhibitor patents?
It covers a specific subclass of substituted pyrimidines, similar to other patents in the JAK inhibitor space, but claims are narrower due to structural specifics.
2. Can this patent block generic versions?
Potentially, if the generic compounds fall within the claim scope. Enforcement depends on the similarity of the chemical structures.
3. Are there any oral or injectable formulations claimed in RE47691?
Claims include pharmaceutical compositions, encompassing oral and injectable forms, though specifics depend on dependent claims.
4. What indications are covered under the use claims?
Treatments of diseases mediated by kinase activity, including cancer, autoimmune, and inflammatory diseases.
5. What is the status of patent renewal and maintenance?
Assuming standard maintenance, the patent remains enforceable until around 2030-2035, with renewal fees paid timely.
References
[1] U.S. Patent RE47691. Eli Lilly and Company. 2014.
[2] U.S. Patent 8,650,148. Eli Lilly and Company. 2014.
[3] WIPO Patent Bibliography. (2023). Patent family analysis.
[4] Patent Scope, WIPO. (2023). Kinase inhibitor patent landscape.
Note: Additional patents and prior art searches are advised for comprehensive freedom-to-operate assessments.
More… ↓
⤷ Start Trial
|
